This combination of TOP2A and ADH1B gene diagnostics and clinical lipid panel investigations might be an effective intervention for early and accurate diagnosis, targeted therapy, and improved prognosis of LUAD, thus enhancing the current clinical management strategies of lung cancer. This evidence concerns the gene ADH1B and lung cancer.